• Alpha Tau posted a press release on successful first treatment in its ADMIRE trial using Alpha DaRT for immunocompromised patients with recurrent cSCC.
• Procedure took place at Banner MD Anderson Cancer Center in Arizona; trial targets patients typically excluded from cSCC studies.
• Update follows completion of enrollment in the ReSTART pivotal trial for recurrent cSCC.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alpha Tau Medical Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607150830PRIMZONEFULLFEED9762282) on July 15, 2026, and is solely responsible for the information contained therein.